[Essential thrombocythemia: conventional therapy].
Grossi
A
A
Divisione di Ematologia, Universita di Firenze.
Vannucchi
A M
AM
Longo
G
G
Rafanelli
D
D
Rossi Ferrini
P
P
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007938:Leukemia / Q000209:etiology; D008875:Middle Aged; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D010983:Plateletpheresis; D011087:Polycythemia Vera / Q000628:therapy; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D013927:Thrombosis / Q000209:etiology
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D010761:Phosphorus Radioisotopes; D002066:Busulfan; D006918:Hydroxyurea
Trombocitemia essenziale: la terapia convenzionale.